Abstract: A new and useful hydrophilic polyester fiber and process of making same are disclosed; the fiber has a stable pore system exhibiting a moisture pickup (regain) of at least about 2 percent by weight at 40.degree. C. and a relative humidity of 92%. Our experiments indicate that the proportion of moisture regain is attributable to capillary condensation in an amount of at least 25%. The hydrophilic properties are the result of a certain pore system within the fiber which enables capilliary condensation to occur significantly. The invention describes one way to accomplish this, namely by the addition of a predetermined amount of a suitable oxalato-complex to a suitable polyester mass. Most preferably, about 10% by weight K.sub.3 Al(C.sub.2 O.sub.4).sub.3 is added to the polyester mass.

Abstract: There are disclosed branched chain and cycloaliphatic esters of steroids having the formula: ##STR1## where R is H or CH.sub.3 ;R.sub.1 is H or CH.sub.3 ;R.sub.2 is H or CH.sub.3 ;R.sub.3 is H, OH, CH.sub.3 or Cl;R.sub.4 is H or C.sub.1 to C.sub.4 alkyl;R.sub.5 is H, C.sub.1 to C.sub.4 alkyl or CF.sub.3 ;R.sub.6 is H, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy, halogen or .beta.-OH providing that when R.sub.6 is .beta.-OH, the steroid also contains 9.alpha.-F and further providing that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent at least 4 and at most 5 hydrogen atoms, except in the case of a .DELTA..sup.1,4 -steroid, in which case R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are all hydrogen;R.sub.7 is H or CH.sub.3 ;R.sub.8 is ##STR2## providing the R.sub.8 is --OH or ##STR3## when the steroid has an aromatic ring A.

Abstract: There are disclosed branched chain and cycloaliphatic esters of steroids having the formula: ##STR1## where R is H or CH.sub.3 ;R.sub.1 is H or CH.sub.3 ;R.sub.2 is H or CH.sub.3 ;R.sub.3 is H, OH, CH.sub.3 or Cl;R.sub.4 is H or C.sub.1 to C.sub.4 alkyl;R.sub.5 is H, C.sub.1 to C.sub.4 alkyl or CF.sub.3 ;R.sub.6 is H, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy, halogen or .beta.-OH providing that when R.sub.6 is .beta.-OH, the steroid also contains 9.alpha.-F and further providing that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent at least 4 and at most 5 hydrogen atoms, except in the case of a .DELTA..sup.1,4 -steroid, in which case R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are all hydrogen;R.sub.7 is H or CH.sub.3 ;R.sub.8 is ##STR2## providing the R.sub.8 is --OH or ##STR3## when the steroid has an aromatic ring A and the 3-position is substituted by ##STR4## R.sub.9 is ##STR5## where n is 0, 1 or 2;R.sub.10 is C.sub.1 to C.sub.10 alkyl;R.sub.11 is H or C.sub.

Abstract: The present invention relates to novel biologically active tricyclic compounds of the general formula: ##STR1## and salts thereof, in whichR.sub.1 and R.sub.2 stand for hydrogen, alkyl or alkenyl, an optionally substituted aralkyl group or an acyl group orR.sub.1 +R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ring, andX and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 carbon atoms, nitro, trifluoromethyl or an acyloxy group,which compounds have valuable biological activities, particularly anorectic activity.

Abstract: A new and useful composition of matter is disclosed, having one utility for use in a disposable, reversible thermometer. The novel composition of matter comprises (1) a suitable heat-sensitive composition (for example, as described in U.S. Pat. No. 4,232,552); (2) a suitable matrix-forming amorphous material; and (3) a suitable film-forming material that is more crystalline than the matrix-forming amorphous compound. Preferably, the composition also contains a solubilizing compound.

Abstract: New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-monoquaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters or the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.

Abstract: Novel and biologically active 11.beta.-substituted steroids of the oestrane series are disclosed having the formula ##STR1## wherein (a) R.sub.1 is O or (.alpha.Y)(.beta.Z), wherein Y is selected from the group consisting of H, unsaturated aliphatic hydrocarbons of two to about four carbon atoms, saturated aliphatic hydrocarbons of about one to four carbon atoms, and Z is a free, esterified, or etherified hydroxy group;(b) R.sub.2 is H and R.sub.3 is H or CH.sub.3 ; in the alternative, R.sub.2 and R.sub.3 together constitute a carbon--carbon bond; and(c) ring A has the structure ##STR2## wherein R.sub.4 in compound (II) is a free, esterified, or etherified hydroxyl group, andR.sub.5 in compound (III) is O or is two hydrogens.The new steroids possess oestrogenic, antioestrogenic, progestational, ovulation-inhibiting, uterotropic, androgenic, and anabolic properties for therapeutic administration.

Abstract: The present invention relates to (1) a method for the detection and/or determination of an antigen specific immunoglobulin of a peculiar IgX class, in which X means M, A, D or E, comprising: (a) contacting and reacting the test-medium with either insolubilized anti-IgX against the antigen specific immunoglobulin of a peculiar IgX class to be determined, or antigen binding fragment of this anti-IgX, (2) incubating said contacted and reacted test medium with an antigen for which the immunoglobulin to be determined has specific affinity, and with a labelled antigen binding fragment of an antibody against said antigen, as well as (2) the novel coupling product comprising an antigen immunochemically bound to a labelled antigen binding fragment of an antibody against said antigen, and (3) test kit for the performance of said method (1). The labelling agent is detected and/or determined, which provides qualitative and/or quantitative information about the antigen specific immunoglobulin to be determined.

Abstract: New and pharmacologically useful tetracyclic compounds are disclosed of the formula (I): ##STR1## and pharmaceutically acceptable non-toxic salts therefor, wherein: (a) R is hydrogen, alkyl of one to six carbons, aralkyl of seven to ten carbons, or an acyl group of one to six carbons;(b) R.sub.1, R.sub.2, R.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, alkyl of one to six carbons, alkoxy of one to six carbons, alkythio of one to six carbons, or trifluoromethyl; and(c) R.sub.5 represents hydrogen or an alkyl group of one to six carbons;as well as compositions containing these active compounds and methods of using same. The compounds of the instant invention have a remarkable pharmacological profile--one which clearly indicates the presence of anxiolytic properties with little or no sedative activity. The compounds according to the invention thus possess relatively specific anti-anxiety properties.

Abstract: A temperature indicator including a backing strip with an embossed well stamped therein is provided. The well contains a matrix carrier which is impregnated with a thermally responsive fusible chemical. The bottom of the well is painted a bright color. The impregnated matrix is placed over and substantially covers the colored bottom of the well. The top of the well is covered by a transparent film. At a temperature below a predetermined level, the colored bottom of the well is substantially invisible due to the impregnated matrix being opaque, and at temperatures above such predetermined level, the colored bottom of the well is clearly visible due to the transparency of the impregnated matrix upon melting of the chemical.

Abstract: The invention relates to novel dibenzo[1,2;5,6] cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7] oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7] thiepino pyridine or pyrrole derivatives and dibenzo[b,f] pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, R.sub.2, R.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,m is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: The invention relates to novel dibenzo[1,2;5,6]cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7]oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7]thiepino pyridine or pyrrole derivatives and dibenzo[b,f]pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, R.sub.2, R.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,m is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: The invention relates to novel dibenzo[1,2;5,6] cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7] oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7] thiepino pyridine or pyrrole derivatives and dibenzo[b,f] pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, R.sub.2, R.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,m is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: The present invention relates to novel biologically active tricyclic compounds of the general formula: ##STR1## and salts thereof, in whichR.sub.1 and R.sub.2 stand for hydrogen, alkyl or alkenyl, an optionally substituted aralkyl group or an acyl group orR.sub.1 +R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ring, andX and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 carbon atoms, nitro, trifluoromethyl or an acyloxy group,which compounds have valuable biological activities, particularly anorectic activity.

Abstract: Novel and biologically useful peptides of the formula: A.sub.1 -A.sub.2 -L-Phe-X-L-Thr-L-Ser-R.sub.1 -Y-L-Ser-R.sub.2 -L-Thr-L-Pro-L-Leu-L-Val-L-Thr-B are disclosed (together with pharmaceutical compositions comprising a pharmaceutically effective amount of same) wherein:(a) A.sub.1 and A.sub.2 each represent an aminoacid residue of the formula H.sub.2 N-ALK-CO-, where ALK is an alkylidene group with 1 to 6 carbon atoms inclusively;(b) X is an amino-acid residue selected from the group consisting of L-Met, L-Met(O), L-Met(O.sub.2) and L-Leu;(c) R.sub.1 and R.sub.

Abstract: The invention relates to a new synthesis for the preparation of tetracyclic compounds of the general formula ##STR1## as well as the pharmaceutically acceptable salts thereof, in which: n is the number 1 or 2,m is the number 1, if n=2 and the number 2, if n=1,R.sub.1 and R.sub.2 stand for hydrogen, hydroxy, halogen, lower alkyl (1-4 C), lower alkoxy (1-4 C) or trifluoromethyl andR.sub.3 represents hydrogen, alkyl (1-6 C), aralkyl (7-10 C) or an amino alkyl group (1-6 C), in which the nitrogen atom has been substituted by two alkyl groups (1-4 C), or the nitrogen atom forms part of a heterocyclic 5- or 6-membered ring,having valuable biological properties.

Abstract: An apparatus for use in the colorimetric determination of liquids is disclosed wherein the apparatus is a reaction vessel having a massive V-shaped bottom of transparent material with a refractive index of n.gtoreq.1.4. The bottom has a cone- or prism-shape with an apical angle from about 80.degree. to about 100.degree. or the shape of a polyhedral pyramid whose opposing surfaces intersect at an angle between about 80.degree. and about 100.degree.. The apparatus permits speeded-up colorimetric determinations.

Abstract: A novel method and a novel apparatus therefor are described for detecting and measuring a predetermined immunochemical substance, for example, an antigen, an antibody, a hapten, or certain low molecular weight substance. The detection and measurement of an immunochemical substance using the method and apparatus of the invention involves providing for the agglutination of a suspension of particles in a sample, or color intensity of solutions by which, using the apparatus of the invention to determine certain electromagnetic radiation properties of the sample, the presence and amount of the immunochemical substance can be determined.

Abstract: A novel depletion indicator (time watch) for removable substances containing acid or basic groups is disclosed, together with a novel method of use therefor. The removable substance of a predetermined concentration comes into contact with a suitable pH color indicator that can change color at a predetermined pH range within a much larger measurable pH range, which color change occurs as the concentration of the removable substance diminishes by passing through a permeable film containing both the removable substance and the pH color indicator.The color change occurs at a predetermined time, e.g., the same time that the active ingredient has diminished to the point it is determined to be inactive.

Abstract: A novel combination and a method are disclosed for detecting and measuring a predetermined substance capable of being specifically bound. The combination comprises a novel adapter which eliminates contact of a light conducting and receiving probe with the sample.